ENTRY       D10819                      Drug
NAME        Aflibercept beta (genetical recombination) (JAN)
SEQUENCE    SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDS
            RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKL
            VLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ
            GLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR
            TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
            GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
            DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH
            YTQKSLSLSP GK
            (Disulfide bridge: 30-79, 124-185, 246-306, 352-410, 211-211', 214-214')
  TYPE      Peptide
REMARK      Therapeutic category: 4291
            Product: D10819<JP>
EFFICACY    Antineoplastic, Angiogenesis inhibitor, VEGF inhibitor
TARGET      VEGFA [HSA:7422] [KO:K05448]
            VEGFB [HSA:7423] [KO:K16858]
            PGF [HSA:5228] [KO:K16859]
INTERACTION  
BRITE       Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10819  Aflibercept beta (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                PGF
                 D10819  Aflibercept beta (genetical recombination) (JAN) &lt;JP&gt;
                VEGFA
                 D10819  Aflibercept beta (genetical recombination) (JAN) &lt;JP&gt;
                VEGFB
                 D10819  Aflibercept beta (genetical recombination) (JAN) &lt;JP&gt;
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10819
DBLINKS     PubChem: 319902619
///
